Fig. 7
Comparison of immune TME and HA receptors expression between bladder CIS and normal bladder samples. a Density (cells/mm2) of immune cell populations and tumor cells expressing each HA receptors in bladder CIS collected at baseline and normal bladders. b Density (cells/mm2) of immune cell populations and tumor cells expressing each HA receptors in bladder CIS samples collected after the IP and in normal bladders. Bladder CIS patients were grouped according to the clinical response (NRIP: patients who did not respond to ONCOFID-P-B™ treatment after the intensive phase; CRend: patients with a complete pathological response at the end of the 15-month study; NRMP: patients who relapsed during the maintenance phase). c Density (cells/mm2) of immune cell populations and tumor cells expressing each HA receptors in bladder CIS samples collected after the MP and in normal bladders. Bladder CIS patients were grouped according to the clinical response (CRend: patients with a complete pathological response at the end of the 15-month study; NRMP: patients who relapsed during the maintenance phase). Significantly different data are represented by *p < 0.05 and **p < 0.01. Floating box extends from 25th to 75th percentiles, line through the box indicates median, and bars extend from the smallest to largest values